CN103372071B - A kind of pharmaceutical composition for the treatment of of insomnia patients - Google Patents
A kind of pharmaceutical composition for the treatment of of insomnia patients Download PDFInfo
- Publication number
- CN103372071B CN103372071B CN201210124241.8A CN201210124241A CN103372071B CN 103372071 B CN103372071 B CN 103372071B CN 201210124241 A CN201210124241 A CN 201210124241A CN 103372071 B CN103372071 B CN 103372071B
- Authority
- CN
- China
- Prior art keywords
- parts
- insomnia
- pharmaceutical composition
- present
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 title claims abstract description 34
- 206010022437 insomnia Diseases 0.000 title claims abstract description 34
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 63
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 18
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 18
- 241000208966 Polygala Species 0.000 claims abstract description 16
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 238000009472 formulation Methods 0.000 claims abstract description 3
- 229940079593 drug Drugs 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 19
- 239000002775 capsule Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 22
- 210000004185 liver Anatomy 0.000 abstract description 11
- 238000002360 preparation method Methods 0.000 abstract description 6
- 208000002173 dizziness Diseases 0.000 abstract description 3
- 206010013954 Dysphoria Diseases 0.000 abstract description 2
- 206010019233 Headaches Diseases 0.000 abstract description 2
- 206010033557 Palpitations Diseases 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 231100000869 headache Toxicity 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 210000004243 sweat Anatomy 0.000 abstract description 2
- 239000000284 extract Substances 0.000 description 37
- 241000699666 Mus <mouse, genus> Species 0.000 description 36
- 241000699670 Mus sp. Species 0.000 description 19
- 206010010904 Convulsion Diseases 0.000 description 17
- 230000036461 convulsion Effects 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 238000003304 gavage Methods 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 14
- 239000011049 pearl Substances 0.000 description 12
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 10
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 9
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 8
- 241000256856 Vespidae Species 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 description 8
- 229960002336 estazolam Drugs 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 229960003350 isoniazid Drugs 0.000 description 8
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 8
- 230000001914 calming effect Effects 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 230000008925 spontaneous activity Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241001279009 Strychnos toxifera Species 0.000 description 5
- 241000411851 herbal medicine Species 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 229960005453 strychnine Drugs 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000000114 Pain Threshold Diseases 0.000 description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 3
- 240000002924 Platycladus orientalis Species 0.000 description 3
- 244000292697 Polygonum aviculare Species 0.000 description 3
- 235000006386 Polygonum aviculare Nutrition 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000037040 pain threshold Effects 0.000 description 3
- 229960002275 pentobarbital sodium Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 241000218176 Corydalis Species 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000205407 Polygonum Species 0.000 description 2
- 241000405414 Rehmannia Species 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 241000270708 Testudinidae Species 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 239000005554 hypnotics and sedatives Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 208000020685 sleep-wake disease Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 235000017003 Cissus Nutrition 0.000 description 1
- 241001355260 Cissus Species 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000217407 Margaritifera Species 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000009431 guipi Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000002557 soporific effect Effects 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of pharmaceutical composition for the treatment of of insomnia patients, that the present invention selects is invaluable, spina date seed, polygala root, mother-of-pearl, wilsonii, the fruit of Chinese magnoliavine, Ligusticum wallichii are raw material, is prepared into any conventional oral formulations according to the conventional preparation method of modern preparation process technology. Chinese medicine composition of the present invention has effect of the flat liver of heat-clearing, mental-tranquilization, can improve insomnia and dreamful sleep, forgetful, dysphoria, the micro-hardship of dry, dizzy, the palpitation of having a headache, unconsciously sweat and tire. To stagnant heat in the liver and gall, the insomnia determined curative effect due to having no peace of mind, effect is remarkable.
Description
[technical field]
The present invention relates to a kind of pharmaceutical composition taking vegetable Chinese herbal medicine as raw material, specifically a kind of medicine for the treatment of of insomnia patientsComposition.
[background technology]
Sleep-disorder has now become a kind of epidemic disease. Insomnia is modal sleep-disorder problem, in recent years, and the incidence of disease of insomniaBe the situation rising year by year, become one of modern popular disease. WHO data shows that the whole world exceedes 30% adult and is subject to insomnia tiredDisturb, the insomnia incidence of the U.S. is up to 32%～50%, Britain 10%～14%, Japan 20%, France 30%. Sleep according to ChinaThe up-to-date sleep investigation result that research association announces, China adult insomnia illness rate is up to 57%, higher than the insomnia of developed countriesIncidence, and insomniac's quantity is in continuous increase, and only the domestic market of hypnotic sedative agent in 2010 has exceeded 8,000,000,000 yuan.
The harm of insomnia is apparent, from short-term effect, does not have enough sleep and causes unable, mood One's spirits are drooping, tired outShakiness, absent minded; Long-term insomnia easily causes anxiety disorder, occurs hidrosis, palpitaition simultaneously, is short of breath, trembles, chestThere is constriction in portion, and four limbs do not have the symptoms such as power numbness.
The calm class chemical drug short term efficacy that is used for having a sleepless night is remarkable, but long-term use can cause side effect and withdrawal reaction.
Insomnia is divided into type of hyperactivity of fire caused by deficiency of YIN, type of deficiency of both the heart and spleen, flaring heart fire, type of phlegm-heat attacking internally, type of deficiency of heart-QI and gallbladder-QI by the traditional Chinese medical science, largeAmount bibliographical information has been affirmed the curative effect for the treatment of by Chinese herbs insomnia, as added taste for the guipi decoction of type of deficiency of both the heart and spleen and for type of hyperactivity of fire caused by deficiency of YINTianwang Buxin Dan; The side of calming the nerves of Liu Rongdong etc. (amber end, cortex albiziae, Polygonum multiflower knotweed, the fruit of Chinese magnoliavine, spina date seed, the seed of Oriental arborvitae,Mother-of-pearl, raw dens draconis, raw oyster, wilsonii, Fructus Corni, fushen); Application number is 200810228564.5 the anti-mistake of oneIn the medicine and preparation method thereof of sleeping, disclosing having of preparing taking the red sage root, corydalis tuber, spina date seed, the fruit of Chinese magnoliavine as bulk drug nourishes heartThe anti-insomnia medicine of calming the nerves; Application number is 201012552167.0, the pharmaceutical composition that denomination of invention is a kind for the treatment of of insomnia patients andIn the application of its preparation method, announced formed by red ginseng, the vine of multiflower knotweed, spina date seed, corydalis tuber, cortex albiziae, Radix Glycyrrhizae for godThrough weak, dizzy insomnia, deficiency of blood dreaminess there is nourishing heart, the pharmaceutical composition of the effect of calming the nerves; Application number is 201110073643.2,Denomination of invention is in a kind of medicine for the treatment of of insomnia patients, to disclose with spina date seed, the seed of Oriental arborvitae, mother-of-pearl, Polygonum multiflower knotweed, yncaria stem with hooks, closeWhat joyous flower, fushen, polygala root, keel, the fruit of Chinese magnoliavine, the dried rhizome of rehmannia, Poria cocos, Rhizoma Dioscoreae, astragalus root, Radix Glycyrrhizae were bulk drug has benefitThe peaceful heart of kidney, the intelligence development of calming the nerves, arresting convulsion improving eyesight, tonifying spleen nourishing the stomach, the flat liver of heat-clearing, the pharmaceutical composition of beneficial gas bowl spares; Application number is200910244915.6, in the Chinese medicine composition that denomination of invention is a kind of Cure for insomnia, disclose with yncaria stem with hooks, Radix Angelicae Sinensis, the dried rhizome of rehmannia, whitePrepared by the bulk drugs such as Chinese herbaceous peony, stir-baked SEMEN ZIZIPHI SPINOSAE, the seed of Oriental arborvitae, Radix Achyranthis Bidentatae, chrysanthemum, river rhizoma Gastrodiae have to nourish blood nourishes heart, calming the liver to stop the wind effectPharmaceutical composition.
In summary it can be seen, traditional Chinese medicine in treating insomnia medicine is more, but prescription complexity, active ingredient is indefinite, dose is large, riseThe shortcomings such as the effect time is slow, curative effect time is short, therefore develop have that rapid-action, curative effect time is long, in the sleeping peacefully of determined curative effectMedical instrument is significant.
[summary of the invention]
Object of the present invention is just to work out the pure Chinese medicinal preparation for the treatment of of insomnia patients, overcomes the deficiency of above-mentioned all kinds, and providesOne,, containing hormone, is not had no side effect containing chemical components by pure Chinese medicine, treating both the exterior and interior, determined curative effect, the long energy of curative effect timeReach the medicine of the treatment of insomnia patients of effect of the flat liver of better heat-clearing, mental-tranquilization. This pharmaceutical composition can be for patient in additionNeed to be prepared into different dosage form, be convenient to take, easy to carry.
The pharmaceutical composition for the treatment of of insomnia patients of the present invention, comprises that the bulk drug of following weight parts is made:
Invaluable 3-10 part spina date seed (stir-fry) 10-50 part polygala root (system) 3-10 part
Mother-of-pearl 10-40 part fruit of Chinese magnoliavine 3-10 part Ligusticum wallichii 3-10 part
Wilsonii 10-40 part.
More preferably, the bulk drug that comprises following weight parts is made:
Invaluable 5-8 part spina date seed (stir-fry) 15-40 part polygala root (system) 5-8 part
Mother-of-pearl 15-25 part fruit of Chinese magnoliavine 5-8 part Ligusticum wallichii 5-8 part
Wilsonii 15-25 part.
Best, the bulk drug that comprises following weight parts is made:
8 parts of 25 parts of polygala roots of invaluable 6 parts of spina date seeds (stir-fry) (system)
6 parts of 5 parts of Ligusticum wallichiis of 20 portions of fruit ofs Chinese magnoliavine of mother-of-pearl
20 parts of wilsoniis.
The pharmaceutical composition for the treatment of of insomnia patients of the present invention can be prepared as any formulation of the prior art, be prepared into tablet,Capsule, granule, pill, oral liquid are best.
Preparation method:
A) Concha Margaritifera powder is broken into fine powder, for subsequent use;
B) get invaluable, wilsonii, the fruit of Chinese magnoliavine adds 5～10 times of amounts of its total amount, 5～8 times of amount 60% alcohol extracts two jointlyInferior, extract 0.5～1.5 hour at every turn, filter, merging filtrate, is concentrated into 60 DEG C of liquid extracts of surveying relative density 1.10～1.20;
C) get polygala root (system), spina date seed, Ligusticum wallichii, jointly add the common decoction twice of 6～10 times of water gagings of its total amount, for the first time2 hours, 1.5 hours for the second time, to filter after merging twice decocting liquid, filtrate is reduced to 60 DEG C to survey relative densities is 1.10～1.20Medicinal extract;
D) medicinal extract that powder step being made in a) and step b), c) obtain merges, and stirs evenly.
Add auxiliary material or the agent of flavouring granulation, capsule, tablet, pill or oral liquid.
The bulk drug that the present invention adopts:
Spina date seed have tranquilizing soporific, analgesia, anticonvulsion, strengthen the effects such as immunologic function. Also have obviously with multiple hypnotic sedative agentSynergy.
Invaluable: different name, kerr treebine root and stem (" conventional Chinese herbal medicine color atlas "), stone qin potato, mountain tortoise (" Guangxi Chinese herbal medicine "),Ground tortoise (Nanchuan " conventional Chinese herbal medicine handbook "), (" mountain of papers Chinese herbal medicine ") do not allowed on ground. Property hardship, cold. Sweet, micro-hardship, temperature. ReturnWarp: return liver, stomach warp. Loose stasis of blood hemostasis, detumescence ding-tong. There is analgesia, hypnosis and sedation.
The fruit of Chinese magnoliavine not only has stable effect to central nervous system, and also has anticonvulsant action. Extend the length of one's sleep, reduce certainlyMain activity, has extensive central inhibitory action.
Mother-of-pearl, taste is sweet, salty, cold in nature, returns liver, the heart channel of Hang-Shaoyin. Useful the moon, calming the liver, arresting convulsion hemostasia effect.
Wilsonii, hides micro-hardship, pungent, warm in nature, returns spleen, kidney, the heart channel of Hang-Shaoyin. There are replenishing kidney, strengthening waist, benefiting qi for tranquillization, effect promoting blood circulation and removing obstruction in channels.
Polygala root, bitter, pungent, slightly warm in nature, the thoughts of returning home, kidney, lung channel. Have the intelligence development of calming the nerves, the effect of eliminating the phlegm, subside a swelling.
Ligusticum wallichii, taste is pungent, warm in nature, returns liver, courage, pericardium channel. There are blood-activating and qi-promoting, wind-expelling pain-stopping effect.
The present invention has effect of the flat liver of heat-clearing, mental-tranquilization. Be used for the treatment of stagnant heat in the liver and gall, the insomnia due to having no peace of mind, rightInsomnia and dreamful sleep, forgetful, dysphoria, the micro-hardship of dry, dizzy, the palpitation of having a headache, unconsciously sweat and tire is effective in cure.
Further illustrate below the drug action of the pharmaceutical composition for the treatment of of insomnia patients of the present invention by pharmacodynamics test.
According to " study of tcm new drug guide ", the pharmacodynamics of composition of the present invention comprises the following aspects: observed different agentPharmaceutical composition in amount situation is by testing spontaneous activity in mice and outstanding tail, and it is frightened that strychnine, pentylenetetrazol and isoniazid cause mouseThe test of fainting, mice sleep dosage and sub-threshold dose yellow Jackets Synergism Testing, the impact of mouse hot-plate analgesia test.
1. the impact of dead time when medicine of the present invention is on spontaneous activity in mice and tail suspension
Experimental technique: 60 of mouse, male and female dual-purpose, is divided into 5 groups, 10 every group. The other gavage of drug component 4,2,1g/kg,Control group gives equivalent distilled water, positive controls gavage estazolam sheet 2.4mg/kg. Gavage after administration 30min, by mouseBe placed in spontaneous activity in mice instrument, first adapt to 1min, then measure spontaneous activity in mice number of times in 5min. Measure complete, by littleMouse afterbody is fixed on an iron, upside down apart from desktop 5cm, records the dead time of mouse in 5min. Result is united with SPSSMeter software carries out t inspection, in table 1.
The impact of table 1 medicine of the present invention on normal spontaneous activity in mice
Note: with control group comparison,**P＜0.01。
Result shows, the high, medium and low dosage group of medicine of the present invention can significantly reduce the Assay of spontaneous activity (P < 0.01) of mouse,The dead time (P < 0.01) that high, the middle dosage group of medicine of the present invention can significantly increase mouse while hanging by the feet, represent that medicine of the present invention hasCertain sedation.
2. medicine of the present invention causes the impact of convulsions mouse on strychnine
Experimental technique: 50 of mouse, male and female dual-purpose, is divided into 5 groups, 10 every group. Drug component do not gavage administration 4,2,1g/kg, control group gives isometric(al) distilled water, positive controls gavage estazolam sheet 4.8mg/kg. After administration 30min, everyMouse lumbar injection strychnine 1.8mg/kg, records the indexs such as mice convulsion incubation period, death time, dead animal number. Result is usedThe t of SPSS10.0 statistical software inspection, in table 2.
The impact of table 2 medicine of the present invention on strychnine convulsions mouse
Note:*For comparing P < 0.05 with control group,**For comparing P < 0.01 with control group.
Result shows, high, the middle dosage group of medicine of the present invention can cause mice convulsion time of occurrence by significant prolongation strychnine, of the present inventionHigh dose group can cause mouse diing time (P < 0.05) by significant prolongation strychnine, but strychnine is caused to not obviously protection of dead mouse,Show that medicine of the present invention has certain antagonism to strychnine induced mice convulsions.
3. the impact of medicine pentetrazole convulsions mouse of the present invention
Experimental technique: 50 of mouse, male and female dual-purpose, is divided into 5 groups, 10 every group. The other gavage of drug component 4,2,1g/kg,Control group gives isometric(al) distilled water, positive controls gavage estazolam sheet 4.8mg/kg. Administration 30min, every mouse abdominal cavity notePenetrate pentylenetetrazol 100mg/kg, record the indexs such as mice convulsion incubation period, death time, dead animal number. Result is united with SPSSMeter software carries out t inspection, in table 3.
The impact of table 3 medicine pentetrazole of the present invention convulsions mouse
Note:**For comparing P < 0.01 with control group.
Result shows, the high, medium and low dosage group of medicine of the present invention can necessarily extend pentylenetetrazol and cause the time of occurrence of mice convulsion and deadDie the time, but there was no significant difference (P > 0.05). High, the middle dosage group of medicine of the present invention can significantly reduce pentylenetetrazol and cause mice convulsionDeath toll (P < 0.01). Disclose medicine pentetrazole induced mice convulsions of the present invention and have certain antagonism.
4. medicine of the present invention causes the impact of convulsions mouse on isoniazid
Experimental technique: 50 of mouse, male and female half and half, are divided into 5 groups, 10 every group. The other gavage of drug component 4,2,1g/kg,Control group gives isometric(al) distilled water, positive controls gavage estazolam sheet 4.8mg/kg. Administration 30min, every mouse abdominal cavity notePenetrate isoniazid 30mg/kg, record the indexs such as mice convulsion incubation period, dead animal number. Result is carried out t with SPSS statistical softwareInspection, in table 4.
The impact of table 4 medicine of the present invention on isoniazid convulsions mouse
Note:*For comparing P < 0.05 with control group,**For comparing P < 0.01 with control group.
Result shows, high, the middle dosage group of medicine of the present invention can significant prolongation isoniazid causes the time of occurrence (P < 0.01) of mice convulsion,But isoniazid is caused to the dead unprotect effect of mice convulsion (P > 0.05). Represent that medicine of the present invention has isoniazid induced mice convulsionsCertain antagonism.
5. the impact of medicine of the present invention on sleep dosage yellow Jackets mouse
Experimental technique: 50 of mouse, male and female half and half, are divided into 5 groups, 10 every group. The other gavage of drug component 4,2,1g/kg,Control group gives isometric(al) distilled water, positive controls gavage estazolam sheet 2.4mg/kg. Administration 30min, every mouse abdominal cavity notePenetrate yellow Jackets 40mg/kg, record the indexs such as mouse dropping asleep latency, the length of one's sleep. Result is carried out with SPSS statistical softwareT inspection, in table 5.
The impact of table 5 medicine of the present invention on sleep dosage yellow Jackets mouse
Note:*For comparing P < 0.05 with control group,**For comparing P < 0.01 with control group.
Result shows, the high, medium and low dosage group of medicine of the present invention can significantly shorten sleep dosage pentobarbital sodium in mice while falling asleepBetween (P < 0.01), and the significant prolongation length of one's sleep (P < 0.05). Disclose medicine of the present invention to sleep dosage pentobarbital sodium in miceSleep has certain synergy.
6. the impact of medicine of the present invention on sub-threshold dose yellow Jackets mouse
Experimental technique: 50 of mouse, male and female half and half, are divided into 5 groups, 10 every group. The other gavage of drug component 4,2,1g/kg,Control group gives isometric(al) distilled water, positive controls gavage estazolam sheet 2.4mg/kg. Administration 30min, every mouse abdominal cavity notePenetrate yellow Jackets 30mg/kg, record the mouse indexs such as number of animals of falling asleep. Result is carried out t inspection and card with SPSS statistical softwareSide's inspection, in table 6.
The impact of table 6 medicine of the present invention on sub-threshold dose yellow Jackets mouse
Note:*For comparing P < 0.05 with control group,**For comparing P < 0.01 with control group.
Result shows, medicine of the present invention is high, medium and low can significantly increase the sub-threshold dose yellow Jackets mouse number of animals of falling asleep(P < 0.01). Prompting, medicine of the present invention has certain synergy to hypnosis of pentobarbital sodium of subthreshold dose.
7. the impact of medicine of the present invention on mouse hot plate induced pain
Experimental technique: through prerun, get pain threshold 50 of female mices in 10～30s, be divided into 5 groups, 10 every group. MedicineThing group is gavage 4,2,1g/kg respectively, and control group gives isometric(al) distilled water, positive controls gavage estazolam sheet 2.4mg/kg.Administration 30min, is placed in mouse respectively in 50 ± 1 DEG C of hot-plate instruments, records mouse and licks the metapedes time as pain threshold (in 60s notLick and be recorded as 60s). Result is carried out t inspection with SPSS statistical software, in table 7.
The impact of table 7 medicine of the present invention on mouse hot plate induced pain
Note:*For comparing P < 0.05 with control group.
Result shows, the pain threshold (P < 0.05) that high, the middle dosage group of medicine of the present invention can significant prolongation mouse hot plate. Prompting, thisInvention medicine has certain analgesic activity to hot plate induced pain mouse.
To sum up test explanation, medicine of the present invention, by the inhibitory action to central nervous system, has significant sedative-hypnotic effect.
Drug extract of the present invention, is prepared by embodiment 4, and Chongqing Hil'an Pharmaceutical Co., Ltd provides, lot number 110201.
Proterties: brown medicinal extract. Content: every g medicinal extract is containing crude drug in whole 11.06g. With distilled water diluting to desired concn.
The mouse using in this experiment is Kunming mouse, body weight 18～22g, and Chongqing Institute of Chinese Medicine animal housing provides.
Estazolam sheet, Anhui Bang Ning pharmaceutical Co. Ltd produces, specification 1mg, lot number 100214.
Strychnine, Shanghai reagent two factories, specification 5g, lot number 080622.
Pentylenetetrazol, is provided lot number 064K0686 by sigma company of the U.S..
Isoniazid, Chengdu Jin Hua pharmaceutcal corporation, Ltd, specification 0.1g, lot number 100904.
[detailed description of the invention]
Below in conjunction with embodiment, the pharmaceutical composition for the treatment of of insomnia patients of the present invention is described in further detail.
Embodiment 1
A) get 35 parts of mother-of-pearls and be ground into fine powder, for subsequent use;
B) get 9 parts of invaluable 9 parts, 35 parts of wilsoniis, the fruit of Chinese magnoliavine and jointly add 9 times of amounts of its total amount, 7 times of amount 60% ethanolExtract secondary, extract 1 hour at every turn, filter, merging filtrate, is concentrated into 60 DEG C of liquid extracts of surveying relative density 1.15;
C) get 9 parts of polygala roots (system), 40 parts of spina date seeds, 9 parts of Ligusticum wallichiis, jointly add the common decoction two of 9 times of water gagings of its total amountInferior, 2 hours for the first time, 1.5 hours for the second time, to filter after merging twice decocting liquid, filtrate is reduced to 60 DEG C, and to survey relative densities be 1.10Medicinal extract;
D) medicinal extract that fine powder step being made in a) and step b), c) obtain merges, and stirs evenly.
Embodiment 2
A) get 15 parts of mother-of-pearls and be ground into fine powder, for subsequent use;
B) get invaluable 8 parts, 25 parts of wilsoniis, 8 parts, the fruit of Chinese magnoliavine, jointly add 8 times of amounts of its total amount, 7 times of amount 60% secondAlcohol extracting secondary extracts 1.5 o'clock at every turn, filters, and merging filtrate, is concentrated into 60 DEG C of liquid extracts of surveying relative density 1.15;
C) get 8 parts of polygala roots (system), 15 parts of spina date seeds, 5 parts of Ligusticum wallichiis, jointly add the common decoction two of 8 times of water gagings of its total amountInferior, 2 hours for the first time, 1.5 hours for the second time, to filter after merging twice decocting liquid, filtrate is reduced to 60 DEG C, and to survey relative densities be 1.15Medicinal extract;
D) medicinal extract that fine powder step being made in a) and step b), c) obtain merges, and stirs evenly.
Embodiment 3
A) get 25 parts of mother-of-pearls and be ground into fine powder, for subsequent use;
B) get 5 parts of invaluable 5 parts, 15 parts of wilsoniis, the fruit of Chinese magnoliavine and jointly add 7 times of amounts of its total amount, 6 times of amount 60% ethanolExtract secondary, extract 1 hour at every turn, filter, merging filtrate, is concentrated into 60 DEG C of liquid extracts of surveying relative density 1.20;
C) get 5 parts of polygala roots (system), 40 parts of spina date seeds, 8 parts of Ligusticum wallichiis, jointly add the common decoction two of 7 times of water gagings of its total amountInferior, 2 hours for the first time, 1.5 hours for the second time, to filter after merging twice decocting liquid, filtrate is reduced to 60 DEG C, and to survey relative densities be 1.20Medicinal extract;
D) medicinal extract that fine powder step being made in a) and step b), c) obtain merges, and stirs evenly.
Embodiment 4
A) get 20 parts of mother-of-pearls and be ground into fine powder, for subsequent use;
B) get invaluable 6 parts, 20 parts of wilsoniis, 5 parts, the fruit of Chinese magnoliavine, jointly add 8 times of amounts of its total amount, 6 times of amount 60% secondAlcohol extracting secondary extracts 1 hour at every turn, filters, and merging filtrate, is concentrated into 60 DEG C of liquid extracts of surveying relative density 1.15;
C) get 8 parts of polygala roots (system), 25 parts of spina date seeds, 6 parts of Ligusticum wallichiis, jointly add the common decoction two of 8 times of water gagings of its total amountInferior, 2 hours for the first time, 1.5 hours for the second time, to filter after merging twice decocting liquid, filtrate is reduced to 60 DEG C, and to survey relative densities be 1.15Medicinal extract;
D) medicinal extract that fine powder step being made in a) and step b), c) obtain merges, and stirs evenly.
Embodiment 5
A) get 30 parts of mother-of-pearls and be ground into fine powder, for subsequent use;
B) get invaluable 6 parts, 25 parts of wilsoniis, the fruit of Chinese magnoliavine and jointly add 6 times of amounts of its total amount, 7 times of amount 60% alcohol extractsSecondary extracts 0.5 hour at every turn, filter, merging filtrate, be concentrated into 60 DEG C survey relative densities 1.10～liquid extract;
C) get 7 parts of polygala roots (system), 30 parts of spina date seeds, 7 parts of Ligusticum wallichiis, jointly add the common decoction two of 6 times of water gagings of its total amountInferior, 2 hours for the first time, 1.5 hours for the second time, to filter after merging twice decocting liquid, filtrate is reduced to 60 DEG C, and to survey relative densities be 1.10Medicinal extract;
D) medicinal extract that fine powder step being made in a) and step b), c) obtain merges, and stirs evenly.
Embodiment 6
A) get 23 parts of mother-of-pearls and be ground into fine powder, for subsequent use;
B) get 5 parts of invaluable 8,22 parts of wilsoniis, the fruit of Chinese magnoliavine and jointly add 7 times of amounts of its total amount, 6 times of amount 60% alcohol extractsSecondary extracts 1 o'clock at every turn, filters, and merging filtrate, is concentrated into 60 DEG C of liquid extracts of surveying relative density 1.15;
C) get 9 parts of polygala roots (system), 25 parts of spina date seeds, Ligusticum wallichii, jointly add the common decoction twice of 8 times of water gagings of its total amount,2 hours for the first time, 1.5 hours for the second time, to filter after merging twice decocting liquid, filtrate is reduced to 60 DEG C to survey relative densities is 1.15Medicinal extract;
D) medicinal extract that fine powder step being made in a) and step b), c) obtain merges, and stirs evenly.
Embodiment 7 prepares tablet
By steps d in arbitrary embodiment in embodiment 1～embodiment 6) in the medicinal extract that makes, add 5% starch of its total amount,Mix, granulation is compressing tablet afterwards, makes the tablet of 0.5g/ sheet.
Embodiment 8 prepares capsule
By steps d in arbitrary embodiment in embodiment 1～embodiment 7) in make 3% the starch that adds its total amount in medicinal extract,Mix, after granulation, dry, pulverize, filled capsules, makes the capsule of 0.5g/ grain.
Embodiment 9 prepares granule
By steps d in arbitrary embodiment in embodiment 1～embodiment 6) in make and in medicinal extract, add its total amount 50% dextrin and 20%Sucrose, granulates, dry, dresses up the granule of 10g/ bag.
Embodiment 10 prepares pill
Using steps d in arbitrary embodiment in embodiment 1～embodiment 6) in make the refined honey that adds its total amount 80% in medicinal extract asAdhesive and 20% starch, mix, and pill is dry, makes honeyed bolus.
Embodiment 11 prepares oral liquid
By steps d in arbitrary embodiment in embodiment 1～embodiment 6) in make medicinal extract and add water to 60 DEG C of relative densities and be 1.05～1.10, mix, pour in oral stable medicinal polythene bottle with high density, obtain oral liquid.
Claims (6)
1. a pharmaceutical composition for Cure for insomnia, is characterized in that being prepared from by the bulk drug of following weight parts:
Invaluable 3-10 part spina date seed 10-50 part polygala root 3-10 part
Mother-of-pearl 10-40 part fruit of Chinese magnoliavine 3-10 part Ligusticum wallichii 3-10 part
Wilsonii 10-40 part.
2. the pharmaceutical composition of a kind of Cure for insomnia as claimed in claim 1, is characterized in that the more excellent proportioning of described bulk drug is:
Invaluable 5-8 part spina date seed 15-40 part polygala root 5-8 part
Mother-of-pearl 15-25 part fruit of Chinese magnoliavine 5-8 part Ligusticum wallichii 5-8 part
Wilsonii 15-25 part.
3. the pharmaceutical composition of a kind of Cure for insomnia as claimed in claim 1, is characterized in that the best proportioning of described bulk drug is:
8 parts of 25 parts of polygala roots of invaluable 6 parts of spina date seeds
6 parts of 5 parts of Ligusticum wallichiis of 20 portions of fruit ofs Chinese magnoliavine of mother-of-pearl
20 parts of wilsoniis.
4. the pharmaceutical composition of the Cure for insomnia as described in as arbitrary in claim 1～3, is characterized in that described composition is prepared as any formulation of the prior art.
5. the pharmaceutical composition of Cure for insomnia as claimed in claim 4, is characterized in that described composition is prepared as any existing pharmaceutical dosage form in tablet, capsule, granule, pill, oral liquid.
6. the pharmaceutical composition as described in arbitrary as described in claim 1～5 is in the application of preparing in medicament for treating insomnia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210124241.8A CN103372071B (en) | 2012-04-25 | 2012-04-25 | A kind of pharmaceutical composition for the treatment of of insomnia patients |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210124241.8A CN103372071B (en) | 2012-04-25 | 2012-04-25 | A kind of pharmaceutical composition for the treatment of of insomnia patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103372071A CN103372071A (en) | 2013-10-30 |
| CN103372071B true CN103372071B (en) | 2016-05-11 |
Family
ID=49458317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210124241.8A Active CN103372071B (en) | 2012-04-25 | 2012-04-25 | A kind of pharmaceutical composition for the treatment of of insomnia patients |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103372071B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104740283A (en) * | 2015-04-13 | 2015-07-01 | 董培良 | Tranquilizing and intelligence-reinforcing capsule for treating insomnia and preparation method thereof |
| CN105641252A (en) * | 2016-02-25 | 2016-06-08 | 胡乃启 | Traditional Chinese medicine preparation for treating senile insomnia and preparation method of traditional Chinese medicine preparation |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1493353A (en) * | 2003-09-18 | 2004-05-05 | 江苏扬子江药业集团有限公司 | Chinese compound medicine for treating anhypnosis and its preparation metod |
| CN1709475A (en) * | 2005-06-22 | 2005-12-21 | 贵州同济堂制药股份有限公司 | Chinese medicine formulation for treating extensive anxiety, and its preparing method |
-
2012
- 2012-04-25 CN CN201210124241.8A patent/CN103372071B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1493353A (en) * | 2003-09-18 | 2004-05-05 | 江苏扬子江药业集团有限公司 | Chinese compound medicine for treating anhypnosis and its preparation metod |
| CN1709475A (en) * | 2005-06-22 | 2005-12-21 | 贵州同济堂制药股份有限公司 | Chinese medicine formulation for treating extensive anxiety, and its preparing method |
Non-Patent Citations (8)
| Title |
|---|
| 刺五加与五味子合用对小鼠镇静催眠作用的研究;胡文婷，等;《中药药理与临床》;20111231;第27卷(第6期);66-68 * |
| 复方枣仁胶囊治疗失眠的疗效观察;陈丽英；等;《辽宁中医杂志》;20021231;第19卷(第11期);669-670 * |
| 安神汤治疗失眠症30例疗效观察;黄淑玲;《新中医》;20050831;第37卷(第8期);26-27 * |
| 杨力强，等.神志不安疾患及安神剂的配伍规律探析.《时珍国医国药》.2009,第20卷(第5期),1275-1276. * |
| 清心安神饮治疗失眠实证60例疗效观察;张志峰;《新中医》;20051231;第37卷(第1期);39-40 * |
| 金不换药材的含量测定;王捷；等;《中国药师》;20051231;第8卷(第5期);391-392 * |
| 镇静安神药联合复方枣仁胶囊治疗失眠症37例;刘彦;《中医杂志》;20091231;第50卷(第增刊期);131-132 * |
| 镇静安神药联合复方枣仁胶囊治疗失眠症的疗效观察;刘彦，许志刚;《临床合理用药》;20120229;第5卷(第2C期);77 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103372071A (en) | 2013-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103039970B (en) | A kind of active component and preparation method thereof of nutrient and healthcare products with resist oxygen lack, antifatigue | |
| CN104069335A (en) | Medicine composition capable of improving sleep quality and preparation method of medicine composition as well as application of medicine composition | |
| CN102008643B (en) | Mixture for treating panasthenia | |
| CN104388265A (en) | Tonic wine for tonifying kidney and preserving health and preparation method thereof | |
| CN105596702A (en) | Traditional Chinese medicine composition with sleep improving function | |
| CN106617000A (en) | Traditional Chinese medicinal composition for enhancing immunity and relieving fatigue, as well as preparation method and application of traditional Chinese medicinal composition | |
| CN101502626B (en) | Medicament for treating influenza and preparation method thereof | |
| CN102895571B (en) | Chinese medicinal preparation for treating insomnia, method for preparing Chinese medicinal preparation for treating insomnia and application of Chinese medicinal preparation for treating insomnia | |
| CN103372071B (en) | A kind of pharmaceutical composition for the treatment of of insomnia patients | |
| CN102552692B (en) | Anoectochilus formosanus compound alcohol-relieving and liver-protecting capsule and preparation method thereof | |
| CN103876137B (en) | There is the traditional Chinese medicine health care product of improving water flood function | |
| JP2018516995A (en) | Pharmaceutical composition for the treatment of depression and method for its preparation | |
| CN105456818A (en) | Traditional Chinese medicine composition containing folium artemisiae argyi and being capable of treating insomnia and preparation method of traditional Chinese medicine composition | |
| CN102274394A (en) | Chinese medicinal composition for treating postnatal constipation | |
| CN109908218A (en) | A kind of Chinese medicine composition that treating liver depression blood stasis type generalized anxiety disorder and its application | |
| CN104435567A (en) | Traditional Chinese medicinal composition containing gynostemma pentaphyllum for treating gout | |
| CN104324346A (en) | Medicine composition with effect of improving sleeping and preparation method thereof | |
| CN100360152C (en) | Medicinal composition for treating insomnia and its preparing process | |
| CN103071080B (en) | Traditional Chinese medicine preparation for treating depressive disorder | |
| CN104906339B (en) | It is a kind of that there is the health food granule for improving sleep function | |
| CN104688882A (en) | TCM (Traditional Chinese Medicine) composition for treating fever in children | |
| CN101297855A (en) | Chinese medicine preparation for treating paralysis agitans | |
| CN100486621C (en) | Chinese medicinal composition for treating hemilateral headache and its preparation method | |
| CN105749199A (en) | Traditional Chinese medicinal composition for warming middle warmer and invigorating spleen, and preparation method thereof | |
| CN104383046A (en) | Medicament for treating infantile diarrhea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: 401520 Hill Road, Hechuan Industrial Park, Chongqing, No. 168 Patentee after: CHONGQING HILAN PHARMACEUTICAL Co.,Ltd. Address before: 401121 Chongqing, Chongqing, North New District, fortune Avenue, No. 19, Chongqing hi tech wealth Park, building, fortune three, building No. 5, A Patentee before: CHONGQING HILAN PHARMACEUTICAL Co.,Ltd. |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A pharmaceutical composition for treating insomnia Effective date of registration: 20220307 Granted publication date: 20160511 Pledgee: Agricultural Bank of China Limited Chongqing Hechuan sub branch Pledgor: CHONGQING HILAN PHARMACEUTICAL Co.,Ltd. Registration number: Y2022500000010 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230303 Granted publication date: 20160511 Pledgee: Agricultural Bank of China Limited Chongqing Hechuan sub branch Pledgor: CHONGQING HILAN PHARMACEUTICAL Co.,Ltd. Registration number: Y2022500000010 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A pharmaceutical composition for treating insomnia Effective date of registration: 20230309 Granted publication date: 20160511 Pledgee: Agricultural Bank of China Limited Chongqing Hechuan sub branch Pledgor: CHONGQING HILAN PHARMACEUTICAL Co.,Ltd. Registration number: Y2023500000019 |